Document is current
Any future updates will be listed below
-
Authors
Fu, Xiaoya
Zhang, Qian
Wagner, Abram L.
Yao, Ye
Xia, Yilan
Wang, Fengge
Lu, Yihan https://orcid.org/0000-0003-4651-9433
-
Funding
Funding for this research was provided by:
Shanghai Jiading District Health Commission (grant no. GWGZLXK-2023-01)
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 21 December 2025
First Online: 27 January 2026
Declarations
:
: YL received the grant from MSD China (4-valent and 9-valent HPV vaccines licensed in China’s mainland) for research in modeling and health economics of HPV vaccination in adolescent girls, and consultation fees from Walwax Biotechnology Co., Ltd (2-valent HPV vaccine licensed in China’s mainland, and a 9-valent HPV vaccine candidate in the clinical trial) and Xiamen Innovax Biotech Co., Ltd (2-valent and 9-valent HPV vaccines licensed in China’s mainland).
: The dataset analyzed during the current study is available from the corresponding author on reasonable request.
: This study was a modeling study using de-identified published data as model inputs. No ethical approval or informed consent was required.
: YL and XF conceived of this study. XF and FW developed and modified the evaluation model. QZ, XF, FW, and YX collected the data and conducted the modeling. XF drafted initial manuscript. YL, YY, QZ, and ALW critically revised the manuscript and helped interpret data. All authors reviewed the final manuscript.
